Public Sector Pension Investment Board Raises Holdings in Certara, Inc. $CERT

Public Sector Pension Investment Board lifted its holdings in Certara, Inc. (NASDAQ:CERT) by 24.9% during the third quarter, Holdings Channel reports. The institutional investor owned 469,910 shares of the company’s stock after purchasing an additional 93,810 shares during the quarter. Public Sector Pension Investment Board’s holdings in Certara were worth $5,742,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CERT. Associated Banc Corp lifted its holdings in Certara by 9.7% in the third quarter. Associated Banc Corp now owns 11,920 shares of the company’s stock valued at $146,000 after acquiring an additional 1,051 shares during the period. Police & Firemen s Retirement System of New Jersey increased its holdings in shares of Certara by 2.5% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 45,745 shares of the company’s stock valued at $535,000 after purchasing an additional 1,136 shares in the last quarter. Versant Capital Management Inc lifted its stake in shares of Certara by 66.7% in the third quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after purchasing an additional 1,153 shares during the period. Osaic Holdings Inc. boosted its holdings in Certara by 50.7% during the second quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock worth $41,000 after buying an additional 1,175 shares in the last quarter. Finally, ANTIPODES PARTNERS Ltd grew its position in Certara by 22.5% during the second quarter. ANTIPODES PARTNERS Ltd now owns 6,665 shares of the company’s stock worth $78,000 after buying an additional 1,223 shares during the period. Institutional investors and hedge funds own 73.96% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Certara from a “buy” rating to a “hold” rating in a research report on Sunday. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Certara in a research note on Monday, December 29th. Morgan Stanley decreased their target price on Certara from $16.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 18th. KeyCorp lowered their target price on Certara from $13.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, January 8th. Finally, BMO Capital Markets assumed coverage on Certara in a research note on Thursday, November 13th. They set a “market perform” rating and a $9.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $12.82.

Certara Stock Performance

Certara stock opened at $6.53 on Thursday. Certara, Inc. has a fifty-two week low of $6.44 and a fifty-two week high of $15.38. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of 93.29 and a beta of 1.47. The stock has a fifty day moving average of $8.66 and a two-hundred day moving average of $10.07. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.09 and a current ratio of 2.09.

Certara Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.